

~~10/515,678~~

10/518,647

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 3 JAN 16 CA/CAPplus Company Name Thesaurus enhanced and reloaded  
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification  
data  
NEWS 6 JAN 22 CA/CAPplus updated with revised CAS roles  
NEWS 7 JAN 22 CA/CAPplus enhanced with patent applications from India  
NEWS 8 JAN 29 PHAR reloaded with new search and display fields  
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000  
in  
multiple databases  
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 13 FEB 26 MEDLINE reloaded with enhancements  
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000  
to 300,000 in multiple databases  
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 19 MAR 16 CASREACT coverage extended  
NEWS 20 MAR 20 MARPAT now updated daily  
NEWS 21 MAR 22 LWPI reloaded  
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 26 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records  
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 28 MAY 01 New CAS web site launched  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

10/515,678

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:06:02 ON 02 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:06:17 ON 02 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

DICTIONARY FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10518647.str

10/515,678



chain nodes :

10

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

7-8 7-10 8-9

exact bonds :

5-7 6-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom

10:CLASS

L1 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 11:06:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS

24 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 736 TO 1664

PROJECTED ANSWERS: 187 TO 773

L2 24 SEA SSS SAM L1

10/515,678

=> s l1 ful

FULL SEARCH INITIATED 11:06:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1404 TO ITERATE

100.0% PROCESSED 1404 ITERATIONS

562 ANSWERS

SEARCH TIME: 00.00.01

L3 562 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 11:07:01 ON 02 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2007 VOL 146 ISS 19

FILE LAST UPDATED: 1 May 2007 (20070501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 739 L3

=> s l4 and (myocardia? or cardia? or heart or ischemi?)

68156 MYOCARDIA?

132425 CARDIA?

342746 HEART

28861 HEARTS

344655 HEART

(HEART OR HEARTS)

87325 ISCHEMI?

191 ISCHEM

191 ISCHEM



10/515,678

(ISCHEM)  
87348 ISCHEMI?  
(ISCHEMI? OR ISCHEM)

L5 82 L4 AND (MYOCARDIA? OR CARDIA? OR HEART OR ISCHEMI?)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.56	187.87

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:16:38 ON 02 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8  
DICTIONARY FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\105186471.str

10/515,678



chain nodes :  
10 13  
ring nodes :  
1 2 3 4 5 6 7 8 9  
chain bonds :  
7-10 8-13  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9  
exact/norm bonds :  
7-8 7-10 8-9 8-13  
exact bonds :  
5-7 6-9  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 :

10/515,678

G1: Cy, Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:CLASS 13:CLASS

L6 STRUCTURE UPLOADED

=> s l6

SAMPLE SEARCH INITIATED 11:16:54 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS 24 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 736 TO 1664  
PROJECTED ANSWERS: 187 TO 773

L7 24 SEA SSS SAM L6

=> s l6 ful

FULL SEARCH INITIATED 11:17:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1404 TO ITERATE

100.0% PROCESSED 1404 ITERATIONS 535 ANSWERS  
SEARCH TIME: 00.00.01

L8 535 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	359.97

FILE 'CAPLUS' ENTERED AT 11:17:15 ON 02 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

10/515,678

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2007 VOL 146 ISS 19  
FILE LAST UPDATED: 1 May 2007 (20070501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l8

L9 727 L8

=> s l8 and (myocardia? or cardia? or heart or ischemi?)

727 L8  
68156 MYOCARDIA?  
132425 CARDIA?  
342746 HEART  
28861 HEARTS  
344655 HEART  
(HEART OR HEARTS)  
87325 ISCHEMI?  
191 ISCHEM  
191 ISCHEM  
(ISCHEM)  
87348 ISCHEMI?  
(ISCHEMI? OR ISCHEM)

L10 82 L8 AND (MYOCARDIA? OR CARDIA? OR HEART OR ISCHEMI?)

=> d his

(FILE 'HOME' ENTERED AT 11:06:02 ON 02 MAY 2007)

FILE 'REGISTRY' ENTERED AT 11:06:17 ON 02 MAY 2007

L1 STRUCTURE UPLOADED

L2 24 S L1

L3 562 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:07:01 ON 02 MAY 2007

L4 739 S L3

L5 82 S L4 AND (MYOCARDIA? OR CARDIA? OR HEART OR ISCHEMI?)

FILE 'REGISTRY' ENTERED AT 11:16:38 ON 02 MAY 2007

L6 STRUCTURE UPLOADED

L7 24 S L6

L8 535 S L6 FUL

FILE 'CAPLUS' ENTERED AT 11:17:15 ON 02 MAY 2007

L9 727 S L8

L10 82 S L8 AND (MYOCARDIA? OR CARDIA? OR HEART OR ISCHEMI?)

10/515,678

=> dup rem 15 110

PROCESSING COMPLETED FOR L5

PROCESSING COMPLETED FOR L10

L11 82 DUP REM L5 L10 (82 DUPLICATES REMOVED)

=> d 111 ibib hitstr abs 1-82

L11 ANSWER 12 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 12

ACCESSION NUMBER: 2005:1293731 CAPLUS

DOCUMENT NUMBER: 144:101034

TITLE: Application of benzoisoselenazolones in treating ischemic myocardial damage

INVENTOR(S): Wang, Xiaoliang; Guo, Zongru; Lu, Jing; Chu, Fengming;

PATENT ASSIGNEE(S): Pan, Yaping; Wang, Ling  
Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 72 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1572295	A	20050202	CN 2003-142553	20030613
PRIORITY APPLN. INFO.:			CN 2003-142553	20030613


OTHER SOURCE(S): MARPAT 144:101034

I

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(application of benzoisoselenazolones in treating ischemic myocardial damage)

RN 60940-34-3 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



RN 81744-04-9 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-phenyl- (9CI) (CA INDEX NAME)

10/515,678




RN 81744-06-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-phenyl- (9CI) (CA INDEX NAME)




RN 81744-09-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RN 81744-12-9 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 89780-20-1 CAPLUS


10/515,678

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 89780-21-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-hydroxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 89780-23-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 89780-24-5 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 89780-25-6 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 89780-26-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 89780-27-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 89780-28-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 89780-29-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



10/515,678




RN 89780-30-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,6-dichloro-3-pyridinyl)- (9CI)

(CA

INDEX NAME)




RN 89780-31-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dimethyl-2-pyridinyl)- (9CI)

(CA


INDEX NAME)



RN 89802-70-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-3-pyridinyl)- (9CI) (CA

INDEX NAME)




10/515,678

RN 99804-26-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,6-dimethyl-4-pyrimidinyl)- (9CI)  
(CA


INDEX NAME)



RN 99804-27-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dimethyl-2-pyrimidinyl)- (9CI)  
(CA

INDEX NAME)



RN 99804-28-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-pyrazinyl- (9CI) (CA INDEX NAME)



RN 106937-68-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinylmethyl)- (9CI) (CA INDEX  
NAME)

10/515,678




RN 106966-77-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)




RN 124154-69-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RN 135024-94-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-phenyl- (9CI) (CA INDEX NAME)




10/515,678

RN 178403-72-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639520-53-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-[2-(2,5-dihydro-1H-imidazol-2-yl)ethenyl]- (9CI) (CA INDEX NAME)



RN 639520-56-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(8-quinolinyl)- (9CI) (CA INDEX NAME)




RN 639520-60-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-[4-[1-(hydroxyimino)ethyl]phenyl]- (9CI)


(CA INDEX NAME)

10/515,678




RN 639520-61-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-butyl-1,3-dihydro-3-oxo-5-isobenzofuranyl)- (9CI) (CA INDEX NAME)



RN 639520-64-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639520-66-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10/515,678



RN 639520-67-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(3-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-68-6 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)



RN 639520-71-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(4-pyridinyl)- (9CI) (CA  
INDEX NAME)



10/515,678


RN 639520-72-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 639520-73-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 639520-74-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639520-76-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)


10/515,678



RN 639520-77-7 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 5-fluoro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-79-9 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 5-fluoro-2-(3-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-80-2 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 5-fluoro-2-(4-pyridinyl)- (9CI) (CA

INDEX  
NAME)






10/515,678


RN 639520-82-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-fluoro-2-phenyl- (9CI) (CA INDEX NAME)




RN 639520-84-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639520-86-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-fluoro-2-phenyl- (9CI) (CA INDEX NAME)



RN 639520-90-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-phenyl- (9CI) (CA INDEX NAME)

10/515,678




RN 639520-93-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 639520-96-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 639520-98-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




10/515,678

RN 639521-00-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(3-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-02-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-04-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-05-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)


10/515,678



RN 639521-07-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-09-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-fluoro-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-10-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-fluoro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)


10/515,678



RN 639521-11-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 4-fluoro-2-(4-pyridinyl)- (9CI) (CA  
INDEX  
NAME)




RN 639521-12-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-(2-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RN 639521-13-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-(3-pyridinyl)- (9CI) (CA  
INDEX  
NAME)


10/515,678



RN 639521-14-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-15-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-16-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)

10/515,678




RN 639521-17-8 CAPLUS

CN 1,2-Benzisosenazol-3(2H)-one, 4-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-18-9 CAPLUS

CN 1,2-Benzisosenazol-3(2H)-one, 4-hydroxy-2-(3-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-19-0 CAPLUS


CN 1,2-Benzisosenazol-3(2H)-one, 4-hydroxy-2-(4-pyridinyl)- (9CI) (CA  
INDEX NAME)



10/515,678


RN 639521-20-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(3-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-21-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-22-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(3-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-23-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(4-pyridinyl)- (9CI) (CA  
INDEX NAME)




10/515,678




RN 639521-24-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 639521-25-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639521-26-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




10/515,678

RN 639521-27-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,6-dihydro-6-oxo-2-pyridinyl)-  
(9CI)


(CA INDEX NAME)



RN 639521-28-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-nitro-2-pyridinyl)- (9CI) (CA  
INDEX


NAME)



RN 639521-29-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methyl-2-(2-pyridinyl)- (9CI) (CA  
INDEX


NAME)



RN 639521-30-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methoxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)


10/515,678



RN 639521-31-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-nitro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-32-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-(2-pyridinyl)- (9CI) (CA


INDEX NAME)



RN 639521-34-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-methyl-2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




10/515,678

RN 639521-35-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-36-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-methyl-2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-37-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methyl-2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-38-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3,5-dichloro-2-pyridinyl)- (9CI)

(CA  
INDEX NAME)


10/515,678



RN 639521-39-4 CAPLUS


CN 1,2-Benziselenazol-3(2H)-one, 2-(4-chloro-2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-40-7 CAPLUS

CN 4-Pyridinecarboxylic acid,  
5-chloro-2-(3-oxo-1,2-benziselenazol-2(3H)-  
yl)- (9CI) (CA INDEX NAME)



RN 639521-41-8 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-(3-oxo-1,2-benziselenazol-2(3H)-yl)-  
(9CI)  
(CA INDEX NAME)



10/515,678


RN 639521-42-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 639521-43-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-44-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-ethoxy-2-(ethylthio)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 639521-45-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,2-dihydro-2-oxo-4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-, ethyl ester (9CI) (CA INDEX NAME)

10/515,678




RN 639521-46-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI) (CA INDEX NAME)



RN 639521-47-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[6-chloro-2-(methylthio)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 639521-48-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chloro-6-methyl-2-pyrimidinyl)-  
(9CI)  
(CA INDEX NAME)


10/515,678



RN 639521-49-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-chloro-5-nitro-4-pyrimidinyl)-  
(9CI)


(CA INDEX NAME)



RN 639521-50-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dichloro-2-pyrimidinyl)- (9CI)  
(CA

INDEX NAME)




RN 639521-51-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dichloro-5-pyrimidinyl)- (9CI)  
(CA

INDEX NAME)




10/515,678




RN 639521-52-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-hydroxy-4-oxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-53-2 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 6-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI)  
(CA INDEX NAME)



RN 639521-54-3 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 5-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI)  
(CA INDEX NAME)

10/515,678




RN 639521-55-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-mercapto-4-thioxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-56-5 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,3,6-tetrahydro-6-oxo-2-thioxo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-57-6 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-[1,6-dihydro-2-(methylthio)-6-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/515,678




RN 639521-58-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-59-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-60-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

10/515,678




RN 639521-61-2 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 1,5-dihydro-4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI) (CA INDEX NAME)



RN 639521-62-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dihydro-6-thioxo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)




RN 639521-63-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2-dihydro-2-oxo-4-pyrimidinyl)- (9CI)

10/515,678


(CA INDEX NAME)



RN 639521-64-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chloro-2-benzothiazolyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-65-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methoxy-2-benzothiazolyl)- (9CI)  
(CA

INDEX NAME)




RN 639521-66-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-2-benzothiazolyl)- (9CI)  
(CA

INDEX NAME)


10/515,678



RN 639521-67-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-benzothiazolyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-68-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-methyl-5-benzothiazolyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-69-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-nitro-2-benzothiazolyl)- (9CI)  
(CA

INDEX NAME)




10/515,678

RN 639521-70-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-bromo-2-benzothiazolyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-71-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-2-benzothiazolyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-72-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-ethoxy-2-benzothiazolyl)- (9CI)  
(CA

INDEX NAME)




RN 639521-73-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methyl-2-(2-thiazolyl)- (9CI) (CA  
INDEX

NAME)


10/515,678



RN 639521-74-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(2-thiazolyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-75-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methoxy-2-(2-thiazolyl)- (9CI) (CA


INDEX NAME)



RN 639521-76-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-nitro-2-(2-thiazolyl)- (9CI) (CA

INDEX  
NAME)



RN 639521-77-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(2-thiazolyl)- (9CI) (CA

INDEX




10/515,678

NAME)




RN 639521-78-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)




RN 639521-80-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-thiazolyl)- (9CI) (CA  
INDEX NAME)



RN 639521-81-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-thiazolyl)- (9CI) (CA  
INDEX NAME)




10/515,678

RN 639521-82-7 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-chloro-2-thiazolyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-83-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-methyl-5-isothiazolyl)- (9CI) (CA  
INDEX NAME)



RN 639521-84-9 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-imidazol-2-yl)- (9CI) (CA INDEX  
NAME)



RN 639521-85-0 CAPLUS


CN 1H-Imidazole-4-carboxylic acid,  
2-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-,  
ethyl ester (9CI) (CA INDEX NAME)

10/515,678




RN 639521-86-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 639521-87-2 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI)  
(CA INDEX NAME)




RN 639521-88-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid,  
3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-,  
ethyl ester (9CI) (CA INDEX NAME)


10/515,678



RN 639521-89-4 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid,  
5-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-1-  
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639521-90-7 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-phenyl-1H-pyrazol-5-yl)- (9CI)  
(CA INDEX NAME)




RN 639521-91-8 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(4,5-dihydro-5-oxo-1-phenyl-1H-pyrazol-3-  
yl)- (9CI) (CA INDEX NAME)


10/515,678




RN 639521-92-9 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-hydroxy-1H-pyrazol-3-yl)- (9CI)  
(CA INDEX NAME)



RN 639521-93-0 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 639521-94-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 639521-95-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI)

10/515,678


(CA INDEX NAME)




RN 639521-96-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-  
yl]- (9CI) (CA INDEX NAME)



RN 639521-97-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-  
2-yl]- (9CI) (CA INDEX NAME)




RN 639521-98-5 CAPLUS  
CN Pyrazinecarboxylic acid, 3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI)  
(CA INDEX NAME)



10/515,678


RN 639521-99-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-benzimidazol-2-yl)- (9CI) (CA  
INDEX  
NAME)




RN 639522-00-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-1H-benzimidazol-2-yl)-  
(9CI) (CA INDEX NAME)



RN 639522-01-3 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-benzotriazol-5-yl)- (9CI) (CA  
INDEX  
NAME)



RN 639522-02-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-chloro-1,2,4-benzotriazin-3-yl)-  
(9CI) (CA INDEX NAME)

10/515,678




RN 639522-03-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,4-benzotriazin-3-yl)- (9CI) (CA INDEX NAME)



RN 639522-04-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-bromo-1,2,4-benzotriazin-3-yl)- (9CI)  
(CA INDEX NAME)




RN 639522-05-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-fluoro-1,2,4-benzotriazin-3-yl)- (9CI) (CA INDEX NAME)




10/515,678




RN 639522-06-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-nitro-1,2,4-benzotriazin-3-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639522-07-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-benzo[b]thien-2-yl- (9CI) (CA INDEX  
NAME)



RN 639522-08-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-benzo[b]thien-3-yl- (9CI) (CA INDEX  
NAME)



10/515,678


RN 639522-09-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 639522-10-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,1,3-benzothiadiazol-4-yl)- (9CI)  
(CA INDEX NAME)



RN 639522-11-5 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(1,4,5,6-tetrahydro-4,6-dithioxo-1,3,5-  
triazin-2-yl)- (9CI) (CA INDEX NAME)




RN 639522-12-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-diphenyl-1,2,4-triazin-3-yl)-  
(9CI)  
(CA INDEX NAME)


10/515,678




RN 639522-13-7 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-1,2,4-triazin-3-yl)-  
(9CI)  
(CA INDEX NAME)



RN 639522-14-8 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(2,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-  
yl)- (9CI) (CA INDEX NAME)




RN 639522-15-9 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-tetrazol-5-yl)- (9CI) (CA INDEX  
NAME)



10/515,678


RN 639522-16-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-quinolinyl)- (9CI) (CA INDEX NAME)




RN 639522-17-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-methyl-4-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-18-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-nitro-5-quinolinyl)- (9CI) (CA INDEX NAME)




RN 639522-19-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,3,4-tetrahydro-8-quinolinyl)- (9CI)


10/515,678

(CA INDEX NAME)




RN 639522-20-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-21-7 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-22-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-8-quinolinyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 639522-23-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-24-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-25-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)

10/515,678




RN 639522-26-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2H-isoindol-5-yl)- (9CI) (CA INDEX NAME)




RN 639522-30-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(9-ethyl-9H-carbazol-3-yl)- (9CI)  
(CA INDEX NAME)



RN 639522-65-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-piperidinyl)- (9CI) (CA INDEX NAME)




10/515,678


RN 639522-68-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(dihydro-2-thiazolyl)- (9CI) (CA  
INDEX NAME)

CM 1


CRN 639522-67-1  
CMF C10 H10 N2 O S Se



RN 872591-39-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4H-1,2,4-triazol-4-yl)- (9CI) (CA  
INDEX NAME)




RN 872591-49-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indazol-5-yl)- (9CI) (CA INDEX  
NAME)



RN 872591-51-0 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-chloro-1H-indazol-3-yl)- (9CI)  
(CA INDEX NAME)




10/515,678




RN 872591-53-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 872591-55-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indazol-7-yl)- (9CI) (CA INDEX NAME)



GI



AB The title benzoisoselenazolones are represented by formula I (R1 = H,

halogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, trifluoromethyl, nitro, bis-(C1-4 alkyl)-amine; R2 = hydrocarbon chain; R3 = substituted or unsubstituted Ph, or heterocycles containing 1-4 N, O, S). The benzoisoselenazolones have effects in selectively inhibiting Na/Ca exchanger, dilating the coronary artery, and decreasing the oxygen-consumption of cardiac muscle.

L11 ANSWER 23 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 23  
 ACCESSION NUMBER: 2004:2692 CAPLUS  
 DOCUMENT NUMBER: 140:71018  
 TITLE: The use of benzoisoselenazolone compounds against ischemic myocardial damage  
 INVENTOR(S): Wang, Xiaoliang; Gou, Zongru; Lu, Jing; Chu, Fengming;  
 Pan, Yaping; Wang, Ling  
 PATENT ASSIGNEE(S): Institute of Materia, Chinese Academy of Medical Sciences, Peop. Rep. China  
 SOURCE: PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000309	A1	20031231	WO 2003-CN475	20030619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1463972	A	20031231	CN 2002-122664	20020619
CA 2493865	A1	20031231	CA 2003-2493865	20030619
AU 2003278909	A1	20040106	AU 2003-278909	20030619
BR 2003012183	A	20050405	BR 2003-12183	20030619
EP 1541145	A1	20050615	EP 2003-739961	20030619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533798	T	20051110	JP 2004-514522	20030619
IN 2005KN00053	A	20060127	IN 2005-KN53	20050109
US 2006135569	A1	20060622	US 2005-518647	20050705
PRIORITY APPLN. INFO.:			CN 2002-122664	A 20020619
			WO 2003-CN475	W 20030619

10/515,678

OTHER SOURCE(S): MARPAT 140:71018


IT 639521-92-9

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (G140 treatment of ischemic myocardial damage by benzisosenazolone compds.)

RN 639521-92-9 CAPLUS

CN 1,2-Benzisosenazol-3(2H)-one, 2-(5-hydroxy-1H-pyrazol-3-yl)- (9CI)  
(CA

INDEX NAME)




I

RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of ischemic myocardial damage by benzisosenazolone compds.)


RN 81744-06-1 CAPLUS

CN 1,2-Benzisosenazol-3(2H)-one, 6-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RN 81744-09-4 CAPLUS


CN 1,2-Benzisosenazol-3(2H)-one, 5-chloro-2-phenyl- (9CI) (CA INDEX NAME)



10/515,678


RN 89780-23-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 89780-24-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 106937-68-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 106966-77-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 639520-53-9 CAPLUS


10/515,678

CN 1,2-Benzisoselenazol-3(2H)-one, 2-[2-(2,5-dihydro-1H-imidazol-2-yl)ethenyl]- (9CI) (CA INDEX NAME)




RN 639520-56-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(8-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639520-60-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-[4-[1-(hydroxyimino)ethyl]phenyl]- (9CI)  
(CA INDEX NAME)



RN 639520-61-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-butyl-1,3-dihydro-3-oxo-5-isobenzofuranyl)- (9CI) (CA INDEX NAME)


10/515,678



RN 639520-64-2 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 6-fluoro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-66-4 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 6-chloro-2-(4-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639520-67-5 CAPLUS


CN 1,2-Benziselenazol-3(2H)-one, 6-chloro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)


10/515,678




RN 639520-68-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639520-71-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(4-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639520-72-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639520-73-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-phenyl- (9CI) (CA INDEX  
NAME)


10/515,678



RN 639520-74-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(3-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-76-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639520-77-7. CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-fluoro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)






10/515,678


RN 639520-80-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-fluoro-2-(4-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RN 639520-82-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-fluoro-2-phenyl- (9CI) (CA INDEX  
NAME)




RN 639520-84-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(4-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of ischemic myocardial damage by benzoselenazolone compds.)


RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)

10/515,678




RN 81744-04-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-phenyl- (9CI) (CA INDEX NAME)




RN 81744-12-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 89780-20-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 89780-21-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-hydroxy-2-pyridinyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 89780-25-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-chloro-3-pyridinyl)- (9CI) (CA  
INDEX  
NAME)




RN 89780-26-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyrimidinyl)- (9CI) (CA INDEX  
NAME)



RN 89780-27-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 89780-28-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-benzothiazolyl)- (9CI) (CA INDEX  
NAME)


10/515,678




RN 89780-29-0 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-chloro-2-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RN 89780-30-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,6-dichloro-3-pyridinyl)- (9CI)  
(CA  
INDEX NAME)




RN 89780-31-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dimethyl-2-pyridinyl)- (9CI)  
(CA  
INDEX NAME)



10/515,678


RN 89802-70-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99804-26-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,6-dimethyl-4-pyrimidinyl)- (9CI)  
(CA INDEX NAME)



RN 99804-27-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dimethyl-2-pyrimidinyl)- (9CI)  
(CA INDEX NAME)



RN 99804-28-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-pyrazinyl- (9CI) (CA INDEX NAME)

10/515,678




RN 124154-69-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-phenyl- (9CI) (CA INDEX NAME)




RN 135024-94-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-phenyl- (9CI) (CA INDEX NAME)



RN 178403-72-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



10/515,678


RN 639520-79-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-fluoro-2-(3-pyridinyl)- (9CI) (CA  
INDEX  
NAME)




RN 639520-86-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-fluoro-2-phenyl- (9CI) (CA INDEX  
NAME)



RN 639520-90-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-phenyl- (9CI) (CA INDEX  
NAME)



RN 639520-93-7 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-hydroxy-2-phenyl- (9CI) (CA INDEX  
NAME)

10/515,678




RN 639520-96-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-phenyl- (9CI). (CA INDEX NAME)




RN 639520-98-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639521-00-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)






10/515,678

RN 639521-02-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-chloro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-04-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-05-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-07-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-chloro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)

10/515,678




RN 639521-09-8 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 4-fluoro-2-(2-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RN 639521-10-1 CAPLUS


CN 1,2-Benziselenazol-3(2H)-one, 4-fluoro-2-(3-pyridinyl)- (9CI) (CA  
INDEX  
NAME)



RN 639521-11-2 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 4-fluoro-2-(4-pyridinyl)- (9CI) (CA  
INDEX  
NAME)


10/515,678



RN 639521-12-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-(2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-13-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-(3-pyridinyl)- (9CI) (CA

INDEX  
NAME)




RN 639521-14-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)


10/515,678



RN 639521-15-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(3-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-16-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-fluoro-2-(4-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-17-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 4-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)

10/515,678




RN 639521-18-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-hydroxy-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 639521-19-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 4-hydroxy-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639521-20-3 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 5-hydroxy-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



10/515,678


RN 639521-21-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-22-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(3-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-23-6 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-hydroxy-2-(4-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-24-7 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)

10/515,678




RN 639521-25-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 639521-26-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-hydroxy-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 639521-27-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,6-dihydro-6-oxo-2-pyridinyl)- (9CI)  
(CA INDEX NAME)




10/515,678

RN 639521-28-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-nitro-2-pyridinyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-29-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 6-methyl-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)



RN 639521-30-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methoxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-31-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-nitro-2-(2-pyridinyl)- (9CI) (CA

INDEX  
NAME)




10/515,678




RN 639521-32-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-(2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-34-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-methyl-2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-35-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-pyridinyl)- (9CI) (CA  
INDEX NAME)




10/515,678


RN 639521-36-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-methyl-2-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-37-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methyl-2-pyridinyl)- (9CI) (CA  
INDEX NAME)




RN 639521-38-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3,5-dichloro-2-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 639521-39-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chloro-2-pyridinyl)- (9CI) (CA  
INDEX NAME)


10/515,678




RN 639521-40-7 CAPLUS  
CN 4-Pyridinecarboxylic acid,  
5-chloro-2-(3-oxo-1,2-benzisoselenazol-2(3H)-  
yl)- (9CI) (CA INDEX NAME)



RN 639521-41-8 CAPLUS  
CN 3-Pyridinecarboxylic acid, 2-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639521-42-9 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-pyrimidinyl)- (9CI) (CA  
INDEX NAME)



RN 639521-43-0 CAPLUS


10/515,678

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 639521-44-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-ethoxy-2-(ethylthio)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 639521-45-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,2-dihydro-2-oxo-4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 639521-46-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI) (CA INDEX NAME)


10/515,678



RN 639521-47-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[6-chloro-2-(methylthio)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 639521-48-5 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chloro-6-methyl-2-pyrimidinyl)-  
(9CI)  
(CA INDEX NAME)



RN 639521-49-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-chloro-5-nitro-4-pyrimidinyl)-  
(9CI)  
(CA INDEX NAME)


10/515,678



RN 639521-50-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dichloro-2-pyrimidinyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-51-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4,6-dichloro-5-pyrimidinyl)- (9CI)  
(CA


INDEX NAME)



RN 639521-52-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-hydroxy-4-oxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)


10/515,678



RN 639521-53-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI)


(CA INDEX NAME)



RN 639521-54-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI)


(CA INDEX NAME)



RN 639521-55-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-mercapto-4-thioxo-2-  
pyrimidinyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 639521-56-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,3,6-tetrahydro-6-oxo-2-thioxo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-57-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-[1,6-dihydro-2-(methylthio)-6-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 639521-58-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




10/515,678




RN 639521-59-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 639521-60-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)




RN 639521-61-2 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 1,5-dihydro-4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI) (CA INDEX NAME)


10/515,678



RN 639521-62-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(5,6-dihydro-6-thioxo-1H-pyrazolo[3,4-  
d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)




RN 639521-63-4 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2-dihydro-2-oxo-4-pyrimidinyl)-  
(9CI)  
(CA INDEX NAME)



RN 639521-64-5 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chloro-2-benzothiazolyl)- (9CI)  
(CA INDEX NAME)

10/515,678




RN 639521-65-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methoxy-2-benzothiazolyl)- (9CI)

(CA

INDEX NAME)




RN 639521-66-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-2-benzothiazolyl)- (9CI)

(CA

INDEX NAME)




RN 639521-67-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-benzothiazolyl)- (9CI)

(CA

INDEX NAME)




10/515,678

RN 639521-68-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-methyl-5-benzothiazolyl)- (9CI)


(CA  
INDEX NAME)



RN 639521-69-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-nitro-2-benzothiazolyl)- (9CI)


(CA  
INDEX NAME)



RN 639521-70-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-bromo-2-benzothiazolyl)- (9CI)

(CA  
INDEX NAME)




RN 639521-71-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-2-benzothiazolyl)- (9CI)

(CA INDEX NAME)


10/515,678




RN 639521-72-5 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-ethoxy-2-benzothiazolyl)- (9CI)  
(CA INDEX NAME)



RN 639521-73-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 6-methyl-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)




RN 639521-74-7 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 6-chloro-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)



RN 639521-75-8 CAPLUS


10/515,678

CN 1,2-Benzisoselenazol-3(2H)-one, 6-methoxy-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)




RN 639521-76-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-nitro-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)



RN 639521-77-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)



RN 639521-78-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-(2-thiazolyl)- (9CI) (CA  
INDEX NAME)


10/515,678



RN 639521-80-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methyl-2-thiazolyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-81-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-nitro-2-thiazolyl)- (9CI) (CA


INDEX  
NAME)



RN 639521-82-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-chloro-2-thiazolyl)- (9CI) (CA


INDEX  
NAME)



10/515,678


RN 639521-83-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-methyl-5-isothiazolyl)- (9CI) (CA INDEX NAME)




RN 639521-84-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 639521-85-0 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 639521-86-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/515,678



RN 639521-87-2 CAPLUS  
CN 1H-Pyrazole-4-carbonitrile, 3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639521-88-3 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid,  
3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-,  
ethyl ester (9CI) (CA INDEX NAME)




RN 639521-89-4 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid,  
5-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)-1-  
phenyl-, ethyl ester (9CI) (CA INDEX NAME)


10/515,678



RN . 639521-90-7 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-phenyl-1H-pyrazol-5-yl)- (9CI)  
(CA INDEX NAME)




RN 639521-91-8 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(4,5-dihydro-5-oxo-1-phenyl-1H-pyrazol-3-  
yl)- (9CI) (CA INDEX NAME)




RN 639521-93-0 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,3,4-thiadiazol-2-yl)- (9CI) (CA  
INDEX NAME)


10/515,678




RN 639521-94-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-  
yl)- (9CI) (CA INDEX NAME)



RN 639521-95-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-methyl-1,3,4-thiadiazol-2-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639521-96-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-  
yl]- (9CI) (CA INDEX NAME)




RN 639521-97-4 CAPLUS

10/515,678


CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-  
2-yl]- (9CI) (CA INDEX NAME)



RN 639521-98-5 CAPLUS  
CN Pyrazinecarboxylic acid, 3-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI)  
(CA INDEX NAME)




RN 639521-99-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-benzimidazol-2-yl)- (9CI) (CA  
INDEX  
NAME)



RN 639522-00-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-1H-benzimidazol-2-yl)-  
(9CI) (CA INDEX NAME)


10/515,678



RN 639522-01-3 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-benzotriazol-5-yl)- (9CI) (CA

INDEX  
NAME)




RN 639522-02-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-chloro-1,2,4-benzotriazin-3-yl)- (9CI) (CA INDEX NAME)



RN 639522-03-5 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,4-benzotriazin-3-yl)- (9CI) (CA INDEX NAME)



10/515,678


RN 639522-04-6 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-bromo-1,2,4-benzotriazin-3-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639522-05-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-fluoro-1,2,4-benzotriazin-3-yl)-  
(9CI) (CA INDEX NAME)



RN 639522-06-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(7-nitro-1,2,4-benzotriazin-3-yl)-  
(9CI)  
(CA INDEX NAME)



RN 639522-07-9 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-benzo[b]thien-2-yl- (9CI) (CA INDEX  
NAME)

10/515,678




RN 639522-08-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-benzo[b]thien-3-yl- (9CI) (CA INDEX NAME)




RN 639522-09-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 639522-10-4 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2,1,3-benzothiadiazol-4-yl)- (9CI)  
(CA INDEX NAME)




RN 639522-11-5 CAPLUS

10/515,678


CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(1,4,5,6-tetrahydro-4,6-dithioxo-1,3,5-  
triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 639522-12-6 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-diphenyl-1,2,4-triazin-3-yl)-  
(9CI)  
(CA INDEX NAME)




RN 639522-13-7 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5,6-dimethyl-1,2,4-triazin-3-yl)-  
(9CI)  
(CA INDEX NAME)



RN 639522-14-8 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one,  
2-(2,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-  
yl)- (9CI) (CA INDEX NAME)




10/515,678




RN 639522-15-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 639522-16-0 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-17-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-methyl-4-quinolinyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 639522-18-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-nitro-5-quinolinyl)- (9CI) (CA  
INDEX  
NAME)



RN 639522-19-3 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1,2,3,4-tetrahydro-8-quinolinyl)-  
(9CI)  
(CA INDEX NAME)



RN 639522-20-6 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-quinolinyl)- (9CI) (CA INDEX  
NAME)

10/515,678




RN 639522-21-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 639522-22-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-methoxy-8-quinolinyl)- (9CI) (CA INDEX NAME)




RN 639522-23-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1-isoquinolinyl)- (9CI) (CA INDEX NAME)


10/515,678




RN 639522-24-0 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(5-isoquinolinyl)- (9CI) (CA INDEX  
NAME)



RN 639522-25-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indol-5-yl)- (9CI) (CA INDEX  
NAME)




RN 639522-26-2 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2H-isoindol-5-yl)- (9CI) (CA INDEX  
NAME)




RN 639522-27-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(6-chloro-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 639522-28-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indol-6-yl)- (9CI) (CA INDEX NAME)



RN 639522-29-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(1H-indol-7-yl)- (9CI) (CA INDEX NAME)




10/515,678 .

RN 639522-30-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(9-ethyl-9H-carbazol-3-yl)- (9CI)  
(CA

INDEX NAME)




RN 639522-66-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(tetrahydro-2-pyridinyl)- (9CI) (CA  
INDEX NAME)

CM 1

CRN 639522-65-9

CMF C12 H14 N2 O Se



RN 639522-68-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(dihydro-2-thiazolyl)- (9CI) (CA  
INDEX

NAME)

CM 1

CRN 639522-67-1

CMF C10 H10 N2 O S Se



10/515,678

AB The invention disclosed the benzisosenazolone compds. to treat ischemic myocardial damage. Said compds. are highly active and specific with low toxicity, characterized by selectively inhibiting the exchange of Na/Ca, dilating the blood vessel and reducing the amount of oxygen consumed by myocardial tissue.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L11 ANSWER 24 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 24

ACCESSION NUMBER: 2003:97408 CAPLUS

DOCUMENT NUMBER: 138:137428

TITLE: Preparation of seleno compounds containing nitron  
moiety as antioxidants for treatment of acute or  
progressive neurodegenerative disorders

INVENTOR(S): Ko, Sung-Bo; Oh, Eu-Gene; Kim, Eon-Kyeom; Kim,  
Won-Yeob; Choi, Dennis W.; Dugan, Laura L.; Koh,  
Jae-Young; Won, Moo-Bo; Wie, Myung-Bok

PATENT ASSIGNEE(S): Samsung Electronics Co. Ltd., S. Korea

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010154	A1	20030206	WO 2001-KR1275	20010726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001272835	A1	20030217	AU 2001-272835	20010726
US 2003220337	A1	20031127	US 2003-456268	20030606
US 6815459	B2	20041109		

PRIORITY APPLN. INFO.: WO 2001-KR1275 W 20010726

OTHER SOURCE(S): MARPAT 138:137428

IT 494769-23-2P 494769-26-5P 494769-29-8P

494769-30-1P 494769-33-4P 494769-37-8P

494769-40-3P 494769-43-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


10/515,678

(preparation of seleno compds. containing nitron moiety as  
antioxidants for

treatment of acute or progressive neurodegenerative disorders)


RN 494769-23-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[4-[[[(1-methylethyl)oxidoimino]methyl]ph  
enyl]- (9CI) (CA INDEX NAME)




RN 494769-26-5 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one,  
2-[3-[[[(1-methylethyl)oxidoimino]methyl]ph  
enyl]- (9CI) (CA INDEX NAME)



RN 494769-29-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-[3-[[[(1-  
methylethyl)oxidoimino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494769-30-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-methyl-2-[3-[[[(1-  
methylethyl)oxidoimino]methyl]phenyl]- (9CI) (CA INDEX NAME)







10/515,678



RN 494769-43-6 CAPLUS  
 CN 1,2-Benzisoselenazol-3(2H)-one,  
 2-[4-[[[(1-methylethyl)oxidoimino]methyl]ph  
 enyl]-7-nitro- (9CI) (CA INDEX NAME)



GI



AB The present invention provides novel seleno compds. containing nitronium moiety

[I; R1, R2 = H, halogen, C1-4-alkyl, C1-14-alkoxy, hydroxy, trifluoromethyl, nitro; or R1 and R2 together denote methylenedioxy; L

= Ph, C1-4 alkylphenyl, heterocyclic unsatd. or saturated radical having 1 to 4

heteroatoms of elements nitrogen, oxygen, and/or sulfur from the group comprising furanyl, oxazolyl, isooxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, triazinyl, triazolyl, it being possible for the

heterocyclic radical to be substituted once or twice, identically or differently, by halogen, C1-2 alkyl, C1-4 alkoxy, C1-4 alkylthio, hydroxy, mercapto, trifluoromethyl, nitro, Ph, nitrile, carboxy or C1-4 alkoxy carbonyl; R3 = alkyl, substituted alkyl, alkenyl, alkynyl, aralkyl, aryl, cycloalkyl, cycloalkenyl], a process for preparing the same, the use of the novel compds. as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species (ROS) and requiring an antioxidant, in particular stroke, Parkinson's disease, Alzheimer's disease. The compds. of the invention have similar or superior lipid peroxidn. (LPO) inhibition activity to the reference compds. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration. Thus, to a solution of 100 mg N-isopropyl- $\alpha$ -(2-aminothiazol-4-yl)nitron and 0.74 mL Et3N in 15 mL CH2Cl2 was slowly added 220 mg 2-chlorocarbonylbenzeneselenenyl chloride in 5 mL CH2Cl2 at 0° and stirred at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was purified by recrystn. (MeOH/CH2Cl2) to give 70 mg -[4-(N-isopropyl)nitronyl]thiazol-2-yl-1,2-benzisoselenazol-3(2H)-one (II) as a pale yellow solid in 37 % yield. II and 2-[4-(N-isopropyl)nitronyl]phenyl-1,2-benzisoselenazol-3(2H)-one inhibited lipid peroxidn. with IC50 of 1.2 and 81.1  $\mu$ M, resp. vs. 148.3  $\mu$ M for Ebselen.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT


L11 ANSWER 25 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 25  
ACCESSION NUMBER: 2003:355610 CAPLUS  
DOCUMENT NUMBER: 138:348714  
TITLE: Use of peroxy nitrite scavengers or peroxy nitrite  
oxide formation inhibitors that do not diminish nitric  
premature synthesis or activity to reverse or prevent  
vascular senescence  
INVENTOR(S): Goligorsky, Michael S.; Chen, Jun  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 11 pp.  
CODEN: USXXCO

10/515,678

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003086916	A1	20030508	US 2002-269032	20021011
US 2005113427	A1	20050526	US 2004-13457	20041217
PRIORITY APPLN. INFO.:			US 2001-329010P	P 20011012
			US 2002-269032	A1 20021011

IT 60940-34-3, Ebselen  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peroxynitrite scavengers or peroxynitrite formation inhibitors not diminishing nitric oxide synthesis or activity for reversing or preventing premature vascular senescence)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)




AB Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a peroxynitrite scavenger or peroxynitrite formation inhibitor that does not diminish nitric oxide synthesis. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in blood or tissue, e.g., patients with end stage renal disease or poorly controlled diabetes, and in contacting vascular tissue or cells ex vivo to prevent occurrence of premature senescence. Human umbilical vein endothelial cells (HUVEC) after four passages were plated on glycated collagen with or without the addition of 0.1 mM ebselen. Ebselen was able to reverse premature senescence at all dilns. of glycated collagen.

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

10/515,678

L11 ANSWER 29 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 29  
ACCESSION NUMBER: 2003:970225 CAPLUS  
DOCUMENT NUMBER: 140:175017  
TITLE: A novel potent radical scavenger,  
8-(4-fluorophenyl)-2-  
(FR210575),  
((2E)-3-phenyl-2-propenoyl)-1,2,3,4-  
tetrahydropyrazolo[5,1-c][1,2,4]triazine  
prevents neuronal cell death in cultured primary  
neurons and attenuates brain injury after focal  
ischemia in rats  
AUTHOR(S): Iwashita, Akinori; Maemoto, Takuya; Nakada,  
Hirohisa;  
Shima, Ichiro; Matsuoka, Nobuya; Hisajima, Hiroshi  
CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa  
Pharmaceutical Co., Ltd., Ibaraki, Japan  
SOURCE: Journal of Pharmacology and Experimental  
Therapeutics  
(2003), 307(3), 961-968  
CODEN: JPETAB; ISSN: 0022-3565  
PUBLISHER: American Society for Pharmacology and Experimental  
Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 60940-34-3, Ebselen  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(radical scavenger, 8-(4-fluorophenyl)-2-((2E)-3-Ph-2-propenoyl)-  
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (FR210575),  
prevents  
neuronal cell death in cultured primary neurons and attenuates brain  
injury after focal ischemia in rats)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB Reactive oxygen species (ROS) play a vital role in brain damage after  
cerebral ischemia-reperfusion injury, and ROS scavengers have  
been shown to exert neuroprotective effects against ischemic  
brain injury. We have recently identified  
8-(4-fluorophenyl)-2-((2E)-3-  
phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine  
(FR210575) as a novel, powerful free-radical scavenger. In the present

10/515,678

study, the neuroprotective efficacy of FR210575 was evaluated in two neuronal death models in vitro as well as rat focal cerebral ischemia models in vivo. In the first model, primary cortical cultures were exposed to a high oxygen atmospheric (50% O<sub>2</sub>) for 48 h to induce cell death with apoptotic features. Treatment with FR210575 (10-7-10-5 M) significantly inhibited neuronal death. The second model used a growth-factor withdrawal paradigm. Withdrawal of TIP (transferrin, insulin, putrescine and progesterone)-supplemented medium induced apoptotic cell death after 2 days, but treatment with FR210575 exhibited dramatic protection against neuronal death. In two models of cerebral ischemia [photothrombotic occlusion of middle cerebral artery (MCA) for transient model and by permanent MCA occlusion for permanent model], rats received 3-h i.v. infusion (1-10 mg/kg/3 h) of FR210575, with brain damage determined 24 h later. FR210575 (3.2 mg/kg/3 h) significantly reduced the volume of focal damage in the cortex by 36% in the transient model and also reduced the size of ischemic brain damage in the permanent model. These findings indicate that the powerful radical scavenger FR210575 has potent neuroprotective activity and that FR210575 could be an attractive candidate for the treatment of stroke or other neurodegenerative disorders.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L11 ANSWER 39 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 39  
ACCESSION NUMBER: 2001:725086 CAPLUS  
DOCUMENT NUMBER: 136:395793  
TITLE: Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia  
AUTHOR(S): Imai, H.; Masayasu, H.; Dewar, D.; Graham, D. I.; Macrae, I. M.  
CORPORATE SOURCE: Wellcome Surgical Institute and Department of Neuropathology, University of Glasgow, Glasgow, G61 1QH, UK  
SOURCE: Stroke (2001), 32(9), 2149-2156  
CODEN: SJCCA7; ISSN: 0039-2499  
PUBLISHER: Lippincott Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 60940-34-3, Ebselen  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

10/515,678

(neuroprotective efficacy of i.v. ebselen in rodent model of focal cerebral ischemia)

RN 60940-34-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB The neuroprotective efficacy of an i.v. formulation of the antioxidant ebselen has been comprehensively assessed with specific regard to conventional quant. histopathol., subcortical axonal damage, neurol. deficit, and principal mechanism of action. Transient focal ischemia (2 h of intraluminal thread-induced ischemia with 22 h of reperfusion) was induced in the rat. Ebselen (1 mg/kg bolus plus 1 mg/kg per h IV) or vehicle was administered at the start of reperfusion and continued to 24 h. Neurol. deficit was assessed 24 h after ischemia. Gray matter damage was evaluated by quant. histopathol. Axonal damage was determined with amyloid precursor protein immunohistochem. used as a marker of disrupted axonal flow and Tau-1 immunohistochem. to identify oligodendrocyte pathol. Oxidative damage was determined by 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) immunohistochem. Ebselen significantly reduced the volume of gray matter damage in the cerebral hemisphere (by 53.6% compared with vehicle,  $P<0.02$ ). Axonal damage was reduced by 46.8% ( $P<0.002$ ) and the volume of oligodendrocyte pathol. was reduced by 60.9% ( $P<0.005$ ). The neurol. deficit score was reduced by 40.7% ( $P<0.05$ ) and the volume of tissue immunopos. for 8-OHdG and 4-HNE was reduced by 65% ( $P<0.002$ ) and 66% ( $P<0.001$ ), resp., in ebselen-treated animals. Delayed (2-h) treatment with i.v. ebselen significantly reduced gray and white matter damage and neurol. deficit associated with transient ischemia. The reduction in tissue displaying evidence of oxidative stress suggests that the major mechanism of action is attenuation of free radical damage.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L11 ANSWER 43 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 43

10/515,678


ACCESSION NUMBER: 2000:873296 CAPLUS  
DOCUMENT NUMBER: 134:13344  
TITLE: Phenylbenzisoselenazolone derivatives as  
neuroprotectants against brain cell apoptosis  
INVENTOR(S): Nagata, Izumi; Namura, Naotake; Masayasu, Hiroyuki  
PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000344663	A	20001212	JP 1999-151385	19990531
PRIORITY APPLN. INFO.:			JP 1999-151385	19990531

IT 60940-34-3, Ebselen  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(phenylbenzisoselenazolone derivs. as neuroprotectants against brain  
cell apoptosis)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



GI



I


AB Phenylbenzisoselenazolone derivs. (I; R1, R2 = H, halogen,



10/515,678

trifluoromethyl, etc.; R3 = aryl, aromatic hetero cyclic ring, etc.;  
R4 = H,  
OH, -S- $\alpha$ -amino acid, etc.; R5 = H, C1-6 alkyl; Y = O, S; N = 0-5),  
including ebselen, and their physiol. acceptable salts are claimed as  
and neuroprotectants against brain cell apoptosis from cerebral thrombosis  
ischemia-reperfusion injury.

L11 ANSWER 48 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 48  
ACCESSION NUMBER: 2000:776015 CAPLUS  
DOCUMENT NUMBER: 134:40460  
TITLE: Oxidative stress developed during open heart  
surgery induces apoptosis: reduction of apoptotic  
cell  
death by ebselen, a glutathione peroxidase mimic  
AUTHOR(S): Maulik, Nilanjana; Yoshida, Tetsuya  
CORPORATE SOURCE: Department of Surgery, University of Connecticut  
School of Medicine, Farmington, CT, 06030-1110, USA  
SOURCE: Journal of Cardiovascular Pharmacology (2000),  
36(5),  
601-608  
CODEN: JCPCDT; ISSN: 0160-2446  
PUBLISHER: Lippincott Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 60940-34-3, Ebselen  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(effect on oxidative stress associated with apoptosis in relation  
to open  
heart surgery and ischemic-reperfusion injury in swines)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB Apoptosis, a genetically controlled programmed cell death, has been  
found  
to play a role in ischemic reperfusion injury in several animal  
species including rats and rabbits. To examine whether this also is  
true  
for other animals, a surgically relevant model was established using an  
isolated in situ swine heart. Hearts were subjected  
to 15 min of normothermic regional ischemia by left anterior


descending artery (LAD) occlusion followed by 30 min of normothermic cardioplegic arrest and 3 h of reperfusion. Oxygen free radicals have been shown to be the inducers of apoptosis and because reperfusion of ischemic myocardium is associated with the generation of free radicals, an addnl. group of hearts was preperfused with three different doses (5, 10, and 25 nM) ebselen, a glutathione peroxidase mimic, for 15 min before 15 min of LAD occlusion. Hearts were then subjected to 30 min of normothermic cardioplegic arrest followed by 3 h of reperfusion at normothermia. Control expts. were performed by perfusing the hearts for 4 h at normothermia. Two other groups of hearts were subjected to either 30 or 60 min of LAD occlusion followed by 30 min of cardioplegic arrest without subjecting them to reperfusion. At the end of each experiment, hearts were processed for the evaluation of apoptosis and DNA laddering. The in situ end-labeling (ISEL) technique was used to detect apoptotic cardiomyocyte nuclei while DNA laddering was evaluated by subjecting the DNA obtained from the cardiomyocytes to 1.8% agarose gel electrophoresis followed by photographing under UV illumination. The apoptotic cells appeared only after 90 min of reperfusion, as demonstrated by the intense fluorescence of the immunostained genomic DNA when observed under fluorescence microscopy. None of the ischemic hearts showed any evidence of apoptosis. These results were corroborated with the findings of DNA fragmentation showing increased ladders of DNA bands in the same reperfused hearts. The presence of apoptotic cells and DNA fragmentation in the myocardium was abolished by preperfusing the hearts in the presence of 10 nM ebselen, which also moderated the oxidative stress developed in the heart. Apoptotic cells and DNA ladders were completely absent in the hearts subjected to either 30 or 60 min of LAD occlusion. The results demonstrate that reperfusion of the ischemic heart induces apoptosis, which can be reduced with ebselen by reducing the oxidative stress associated with ischemia/reperfusion.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L11 ANSWER 55 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 55  
ACCESSION NUMBER: 1998:780022 CAPLUS  
DOCUMENT NUMBER: 130:231669  
TITLE: Biological activity of Ebselen (Ebs) and its mechanism  
AUTHOR(S): Li, Qiuju; Li, Changling  
CORPORATE SOURCE: Department of Pharmacology, Beijing Medical University, Beijing, 100083, Peop. Rep. China


10/515,678

SOURCE: Zhongguo Yaolixue Tongbao (1998), 14(4), 306-308  
CODEN: ZYTOE8; ISSN: 1001-1978  
PUBLISHER: Anhui Yike Daxue Linchuan Yaoli Yanjiuso  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: Chinese  
IT 60940-34-3, Ebselen  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(anti-inflammatory and other pharmacol. actions of ebselen)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB A review with 27 refs. on biol. activity of Ebs and its mechanism with emphases on (1) pharmacol. activity including anti-inflammatory action, treating hepatitis, treating brain ischemia, anti-sclerosis of arteries, protecting from damage induced by reperfusion after cardiac muscle ischemia, effect on balance of Ca<sup>2+</sup> in platelet, treating stomach ulcer, as supplement drug in treatment of cancer and others, and (2) mechanism of actions.

L11 ANSWER 56 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 56  
ACCESSION NUMBER: 1998:70690 CAPLUS  
DOCUMENT NUMBER: 128:200913  
TITLE: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial  
AUTHOR(S): Yamaguchi, Takenori; Sano, Keiji; Takakura, Kintomo;  
Saito, Isamu; Shinohara, Yukito; Asano, Takao; Yasuhara, Hajime  
CORPORATE SOURCE: National Cardiovascular Center, Osaka, 565, Japan  
SOURCE: Stroke (1998), 29(1), 12-17  
CODEN: SJCCA7; ISSN: 0039-2499  
PUBLISHER: Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 60940-34-3, Ebselen  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ebselen in acute ischemic stroke therapy in humans)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of acute ischemic stroke was evaluated in a multicenter, placebo-controlled, double-blind clin. trial. Patients diagnosed as having acute ischemic stroke who could receive drug treatment within 48 h of stroke onset were enrolled. Oral administration of ebselen granules suspended in water (150 mg BID) or placebo was started immediately after admission and was continued for 2 wk. The major end points were the Glasgow Outcome Scale scores at 1 mo and 3 mo after the start of treatment. The modified Mathew Scale and modified Barthel Index scores at 1 mo and 3 mo were also studied as secondary outcome measures. Three hundred two patients were enrolled in the trial. Intent-to-treat anal. of 300 patients (151 given ebselen and 149 given placebo) revealed that ebselen treatment achieved a significantly better outcome than placebo at 1 mo ( $P=.023$ , Wilcoxon rank sum test) but not at 3 mo ( $P=.056$ , Wilcoxon rank sum test). The improvement was significant in patients who started ebselen within 24 h of stroke onset but not in those who started treatment after 24 h. There was a corresponding improvement in the modified Mathew Scale and modified Barthel Index scores. Early treatment with ebselen improved the outcome of acute ischemic stroke. Ebselen may be a promising neuroprotective agent.


REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L11 ANSWER 57 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 57  
 ACCESSION NUMBER: 1998:107477 CAPLUS  
 DOCUMENT NUMBER: 128:123444  
 TITLE: General pharmacological study of ebselen  
 AUTHOR(S): Takasuna, Kiyoshi; Ono, Hiroshi; Ohara, Naoki; Katsumura, Hideo; Yokota, Syunji; Ishiguro, Yumiko; Shukunobe, Kazuichi; Ogawa, Nobuyuki; Takizawa,

10/515,678

CORPORATE SOURCE: Mihoko; Itokawa, Sachiko  
Japan  
SOURCE: Drug Safety Res. Lab., Daiichi Pharm. Co., Ltd.,  
S/2033-S/2058 Yakuri to Chiryo (1997), 25(Suppl. 9),  
CODEN: YACHDS; ISSN: 0386-3603  
PUBLISHER: Raifu Saiensu Shuppan K.K.  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese  
IT 60940-34-3, Ebselen  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological  
study, unclassified); BIOL (Biological study)  
(general pharmacol. study of ebselen)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)




AB General pharmacol. profile of ebselen, a glutathione peroxidase mimic  
was assessed and the following results were obtained. Ebselen 100  
mg/kg, p.o., showed no effects on most of the tests carried out using  
mice and rats. However, at 1000 mg/kg, p.o., the compound inhibited  
spontaneous activity in mice, and reduced rotating wheel activity in rats.  
Electro-shock-induced seizure in mice was also inhibited by 1000 mg/kg,  
p.o., of ebselen, whereas pentetrazol-induced seizure was not affected.  
Single oral dosing of ebselen at 1000 mg/kg and 7-day repeated dosing  
at 100 mg/kg prolonged sleeping time in mice. The former effect became  
vague when ebselen administered repeatedly for 7 days. By orally  
administered ebselen at 1000 mg/kg the pain responses of mice tested by hot  
plate method tended to be inhibited, and by 1000 mg/kg acetic  
acid-induced writhing in mice also tended to be inhibited. I.v. administered  
ebselen up to 10 mg/kg showed no marked effects on EEG, spinal reflex,  
neuromuscular junction and skeletal muscle, and contraction of the  
nictitating membrane in cats, and on rectal temperature in rabbits.  
However, at 30 mg/kg ebselen produced marked changes in these parameters possibly  
by

severe changes in the cardiovascular parameters in these species. The severe changes in systemic condition led to malfunction of general state and marked influence was observed in these parameters. In anesthetized dogs ebselen caused hypotension at 10 mg/kg, i.v., or more, and cardiac depression was observed after injection of 30 mg/kg. Norepinephrine- and acetylcholine-induced changes in blood pressure were not affected by ebselen. Although in isolated guinea-pig atrium preparation norepinephrine-induced pos. inotropism was inhibited at  $10^{-6}$ M or more, no concentration-dependency was observed. The contractile responses of isolated guinea-pig tracheal preps. to neither acetylcholine nor histamine changed markedly or concentration-dependently by ebselen. The digestive organs tended to be susceptible to ebselen. Charcoal transport through digestive tract in mice, gastric juice secretion and exhaustion of gastric content in rats were inhibited at 1000 mg/kg, 100.apprx.1000 mg/kg and 30.apprx.1000 mg/kg of ebselen, resp. At high concns. ( $10^{-5}$ ,  $10^{-4}$ M) ebselen also inhibited contractile response of isolated guinea-pig ileum to acetylcholine and histamine. In contrast, in anesthetized dogs ebselen facilitated motility of stomach and ileum. Ebselen did not markedly affect rat renal function, but at 1000 mg/kg an increase in sodium resorption rate and decrease in electrolyte clearance were observed. Ebselen had almost no effects on isolated uterus of rat and vas deferens in guinea-pig up to  $10^{-5}$ M, though at  $10^{-4}$ M changes in the responses were observed. Ebselen at 300 and 1000 mg/kg, p.o., inhibited carrageenin-induced hind paw edema in rats. Taken together, ebselen showed weak inhibitory effect on the CNS, mild anti-inflammatory effect, inhibition of electrolyte excretion and changed motility in the digestive organs. Most of these findings were nonspecific effects produced by excessive dosage of ebselen and could not be related to its pharmacol. actions.

L11 ANSWER 59 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 59  
 ACCESSION NUMBER: 1997:751677 CAPLUS  
 DOCUMENT NUMBER: 128:84321  
 TITLE: Neuroprotective efficacy of ebselen, an antioxidant

10/515,678

of with anti-inflammatory actions, in a rodent model  
permanent middle cerebral artery occlusion  
AUTHOR(S): Takasago, T.; Peters, E. E.; Graham, D. I.;  
Masayasu, H.; Macrae, I. M.  
CORPORATE SOURCE: Wellcome Surgical Institute & Hugh Fraser  
Neuroscience  
SOURCE: Labs., University of Glasgow, Glasgow, G61 1QH, UK  
British Journal of Pharmacology (1997), 122(6),  
1251-1256  
CODEN: BJPCBM; ISSN: 0007-1188  
PUBLISHER: Stockton Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 60940-34-3, Ebselen  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(neuroprotective efficacy of ebselen, antioxidant with  
anti-inflammatory actions, in model of permanent focal cerebral  
ischemia)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)




AB The aim of this study was to investigate whether delayed treatment with  
of the antioxidant and anti-inflammatory agent ebselen reduces the volume  
of infarction in a rodent model of permanent focal cerebral ischemia  
min . Ebselen (10 or 30 mg kg<sup>-1</sup>) or vehicle was administered by gavage 30  
and 12 h after the induction of cerebral ischemia by permanent  
occlusion of the left middle cerebral artery (MCA). Animals were  
killed 24 h following MCA occlusion, and the vols. of ischemic damage  
in the ebselen and control groups were evaluated by quant. histopathol.  
Ebselen was quickly absorbed following oral (gavage) administration and  
reached peak levels in the plasma by 1 h post-administration (plasma  
selenium level of 0.68 ± 0.04 and 0.84 ± 0.1 µg ml<sup>-1</sup> for 10 and  
30 mg kg<sup>-1</sup>, resp., compared to control level of 0.51 ± 0.02 µg  
kg<sup>-1</sup>). Treatment with the lower dose of ebselen (10 mg kg<sup>-1</sup>)

significantly ( $P < 0.01$ ) reduced the volume of infarction in the cerebral hemisphere and cerebral cortex (by 31.8% and 36.7%, resp. compared with the placebo group). The neuroprotective efficacy of the higher dose ebselen (30 mg kg<sup>-1</sup>) was less than that of the lower dose ebselen (10 mg kg<sup>-1</sup>). The volume of ischemic damage in the cerebral hemisphere was reduced by 23.7% ( $P < 0.02$ ), and cerebral cortex by 27.5% ( $P < 0.01$ ). Both doses of ebselen (10, 30 mg kg<sup>-1</sup>) had no therapeutic efficacy on the caudate nucleus, where ischemia was most severe, in this model. Free radical-mediated injury is normally associated with reperfusion of ischemic tissue. The present results suggest that oxidative injury is also a significant contributor to brain damage in models of maintained (permanent) ischemia and that ebselen is effective in attenuating this free radical-induced damage.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L11 ANSWER 70 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 70  
 ACCESSION NUMBER: 1992:465957 CAPLUS  
 DOCUMENT NUMBER: 117:65957  
 TITLE: Ebselen. Antioxidant capacity in renal preservation  
 AUTHOR(S): Gower, Jon D.; Lane, Nick J.; Goddard, J. Graham; Manek, Sanjev; Ambrose, Ian J.; Green, Colin J.  
 CORPORATE SOURCE: Sect. Surg. Res., MRC Clin. Res. Cent., Harrow/Middlesex, HA1 3UJ, UK  
 SOURCE: Biochemical Pharmacology (1992), 43(11), 2341-8  
 CODEN: BCPA6; ISSN: 0006-2952  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 60940-34-3, PZ51  
 RL: BIOL (Biological study)  
 (in kidney transplant preservation, antioxidant capacity in relation to)  
 RN 60940-34-3 CAPLUS  
 CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)





AB Ebselen (PZ51) was tested for its ability to inhibit oxidative membrane damage and improve outcome of rabbit kidneys rendered cold ischemic for 72 h. In view of the rapid metabolism of ebselen, the antioxidant capacities of its two principal metabolites were first compared with that of the parent drug in an in vitro hepatic microsomal lipid peroxidn. system initiated by NADPH/Fe<sup>3+</sup>-ADP. The potent antioxidant activity of ebselen was confirmed but metabolite I (2-glucuronylselenobenzanilide) exhibited no antioxidant potential up to a concentration of 50  $\mu$ M; metabolite II (4-hydroxy-2-methylselenobenzanilide) did inhibit lipid peroxidn. but was about 80 times less effective than the parent compound. The storage of rabbit kidneys in hypertonic citrate solution at 0° for 72 h of cold ischemia resulted in greatly increased susceptibility to oxidative membrane damage in both the cortex and medulla as determined by the subsequent in vitro formation of two markers of lipid peroxidn. (Schiff's bases and thiobarbituric acid-reactive material). Inclusion of ebselen (50  $\mu$ M) in the flush and storage solution led to a highly significant reduction in these oxidative markers in both regions of the kidney. Intracellular and interstitial edema was noted in organs subjected to 72 h cold ischemia and was reduced by ebselen (50  $\mu$ M in the flush/storage solution). The rate of post-ischemic lipid peroxidn. was found to correlate well with the extent of edema in the renal medulla, but no such correlation was found in the cortex. Administration of ebselen (5.5 mg/kg i.v. and 100  $\mu$ M in the flush/storage solution) did not improve the long-term survival of rabbits following autotransplantation of a single kidney stored for 48 or 72 h. No protective effect of ebselen could be demonstrated either in terms of graded physiol. function or histol. outcome.


L11 ANSWER 76 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 76  
 ACCESSION NUMBER: 1989:609167 CAPLUS  
 DOCUMENT NUMBER: 111:209167  
 TITLE: 2-Phenyl-1,2-benzoisoselenazol-3(2H)-one for treatment of heart disease  
 INVENTOR(S): Shibano, Toshiro; Tomikawa, Munehiro; Masayasu, Hiroyuki  
 PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 2 pp.

10/515,678

DOCUMENT TYPE: CODEN: JKXXAF  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: Japanese  
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01131114	A	19890524	JP 1988-212002	19880826
KR 9701702	B1	19970214	KR 1988-10865	19880826
PRIORITY APPLN. INFO.:			JP 1987-214789	A1 19870828

IT 60940-34-3  
RL: BIOL (Biological study)  
(pharmaceuticals containing, for heart disease)  
RN 60940-34-3 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)



AB Pharmaceuticals useful for prophylactic and therapeutic treatment of heart disease contain 2-phenyl-1,2-benzisoselenazol-3(2H)-one (I) or its physiol. acceptable salts. After oral administration of I at 100 mg/kg to rats with myocardial infarction, the conditions were improved as reflected by cardiac function, serum creatine phosphokinase concentration, etc. Tablets were formulated containing I 50, CMC 25, starch 5, crystalline cellulose 40, and Mg stearate 2 mg.


L11 ANSWER 80 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 80  
ACCESSION NUMBER: 1988:454669 CAPLUS  
DOCUMENT NUMBER: 109:54669  
TITLE: Diselenobisbenzamides of primary hetero-cyclic amines,  
procedure for their preparation, and pharmaceutical preparations containing them  
INVENTOR(S): Welter, Andre; Roemer, Axel; Leyck, Sigurd; Parnham,  
Michael John  
PATENT ASSIGNEE(S): Nattermann, A., und Cie. G.m.b.H., Fed. Rep. Ger.  
SOURCE: Ger. Offen., 7 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent

10/515,678

LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3626554	A1	19880218	DE 1986-3626554	19860806
EP 257306	A1	19880302	EP 1987-110648	19870723
EP 257306	B1	19900912		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 56436	T	19900915	AT 1987-110648	19870723
CA 1303038	C	19920609	CA 1987-543452	19870730
NO 8703231	A	19880208	NO 1987-3231	19870803
NO 171215	B	19921102		
NO 171215	C	19930210		
FI 8703383	A	19880207	FI 1987-3383	19870804
FI 85018	B	19911115		
FI 85018	C	19920225		
DK 8704090	A	19880207	DK 1987-4090	19870805
DK 169407	B1	19941024		
HU 44572	A2	19880328	HU 1987-3576	19870805
HU 197753	B	19890529		
AU 8776651	A	19880211	AU 1987-76651	19870806
AU 598285	B2	19900621		
ZA 8705821	A	19880330	ZA 1987-5821	19870806
JP 63079875	A	19880409	JP 1987-195406	19870806
JP 08030060	B	19960327		
DD 261597	A5	19881102	DD 1987-305765	19870806
US 4910313	A	19900320	US 1987-82438	19870806
SU 1597097	A3	19900930	SU 1987-4203234	19870806
PRIORITY APPLN. INFO.:			DE 1986-3626554	A 19860806
			EP 1987-110648	A 19870723


OTHER SOURCE(S): CASREACT 109:54669; MARPAT 109:54669  
IT 89780-20-1 89780-24-5 89780-27-8  
106937-67-1 106937-68-2 106966-77-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring cleavage of, with Et mercaptan)  
RN 89780-20-1 CAPLUS  
CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 89780-24-5 CAPLUS


10/515,678

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 89780-27-8 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 106937-67-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 106937-68-2 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 106966-77-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)




IT 106966-78-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring cleavage of, with dithioerythritol)


RN 106966-78-3 CAPLUS

CN 1,2-Benzisosenazol-3(2H)-one, 2-(5-methyl-3-isoxazolyl)- (9CI) (CA  
INDEX NAME)


GI



I



II



III

AB Diselenobisbenzamides I [R1, R2 = H, halo, alkyl, alkoxy, CF3, NO2;  
R1R2 =OCH2O; n = 0, 1; R3 = heterocyclyl with 1-2 hetero atoms (N, S, O)  
(un)substituted with halo, alkyl, alkoxy, NO2, OH], useful in treating  
illnesses resulting from cell damage from increased formation of  
active Ometabolites, e.g. liver damage, heart infarct, inflammation,  
psoriasis, and radiation damage, were prepared by reaction of  
benzisosenazolones II with R'SH (R' undefined) to give intermediate

III

10/515,678

which reacted with MeNH<sub>2</sub>. II (R<sub>1</sub>, R<sub>2</sub> = H, R<sub>3</sub> = 2-furyl, n = 1) in MeOH was treated with EtSH and the mixture stirred 2 h at room temperature to precipitate III

(R<sub>1</sub>-R<sub>3</sub>, n the same, R' = Et) which, in DMF, was treated with 33% MeNH<sub>2</sub> overnight with stirring to give 74.7% I (R<sub>1</sub>, R<sub>2</sub> = H, R<sub>3</sub> = 2-furyl, n = 1)

(IV). In in vitro reduction of H<sub>2</sub>O<sub>2</sub> and organic hydroperoxides the catalytic activity (glutathione peroxidase-like activity), of IV was 82% that of Ebselen.

L11 ANSWER 81 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 81

ACCESSION NUMBER: 1986:514733 CAPLUS

DOCUMENT NUMBER: 105:114733

TITLE: Alkyl carbamoylphenylselenyl sulfide derivatives and

pharmaceutical preparations containing them  
INVENTOR(S): Dereu, Norbert; Wendel, Albrecht; Sies, Helmut; Leyck,

Sigurd; Roemer, Axel; Graf, Erich  
PATENT ASSIGNEE(S): Nattermann, A., und Cie G.m.b.H., Fed. Rep. Ger.  
SOURCE: Ger. Offen., 25 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3443467	A1	19860528	DE 1984-3443467	19841129
EP 187233	A1	19860716	EP 1985-114610	19851116
EP 187233	B1	19880316		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 33022	T	19880415	AT 1985-114610	19851116
US 4730053	A	19880308	US 1985-801561	19851125
DK 8505529	A	19860530	DK 1985-5529	19851128
DK 156474	B	19890828		
DK 156474	C	19900122		
ZA 8509126	A	19860827	ZA 1985-9126	19851128
ES 549367	A1	19861116	ES 1985-549367	19851128
JP 61137856	A	19860625	JP 1985-267590	19851129
JP 06049678	B	19940629		

PRIORITY APPLN. INFO.: DE 1984-3443467 A 19841129

EP 1985-114610 A 19851116

OTHER SOURCE(S): CASREACT 105:114733; MARPAT 105:114733


IT 60940-33-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring opening of, by mercaptans)

RN 60940-33-2 CAPLUS

10/515,678


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 60940-34-3 81744-09-4 101563-19-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring opening of, with Et mercaptan)


RN 60940-34-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)




RN 81744-09-4 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 5-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RN 101563-19-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




10/515,678

IT 81744-10-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring opening of, with mercaptopropionylglycine)

RN 81744-10-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-phenyl- (9CI) (CA INDEX NAME)




IT 81743-92-2


RL: RCT (Reactant); RACT (Reactant or reagent)  
(ring opening of, with thiophenol)

RN 81743-92-2 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



GI



I



II



10/515,678

AB The carbamoylphenylselenenyl sulfide derivs. I [R1 - R4 = H, halo, alkyl, alkoxy, CF3, NO2, cyano, OH, CO2H, alkoxycarbonyl, etc.; A = Ph, HO2CC6H4, alkoxycarbonylphenyl, pyridyl, (un)substituted alkyl; n = 0, 1] are prepared by ring opening of the benzisoselenazolones II with mercaptans ASH. Thus, II (R1 - R4 = H, n = 0) in CHCl3 was treated with EtSH to give I (R1 - R4 = H, A = Et, n = 0). I are drugs for the treatment of cell-damage diseases caused by formation of active O metabolites, such as liver damage, cardiac infarction, inflammations, and radiation sickness. This is based on the glutathione peroxidase-like activity of I, as demonstrated by the method of U. Weser, et al. (1980).

L11 ANSWER 82 OF 82 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 82

ACCESSION NUMBER: 1986:573054 CAPLUS

DOCUMENT NUMBER: 105:173054

TITLE: Glutathione derivatives and pharmaceuticals containing

INVENTOR(S): them  
Dereu, Norbert; Welter, Andre; Wendel, Albrecht; Leyck, Sigurd; Parnham, Michael; Graf, Erich; Sies, Helmut

PATENT ASSIGNEE(S): Nattermann, A., und Cie. G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger. Offen., 17 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 3422962	A1	19860102	DE 1984-3422962	19840622
EP 165534	A2	19851227	EP 1985-107095	19850608
EP 165534	A3	19860514		
EP 165534	B1	19890315		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 41418	T	19890415	AT 1985-107095	19850608
US 4618669	A	19861021	US 1985-744920	19850614
DK 8502829	A	19851223	DK 1985-2829	19850621
DK 156053	B	19890619		
DK 156053	C	19891030		
ZA 8504708	A	19860226	ZA 1985-4708	19850621
JP 61050963	A	19860313	JP 1985-134450	19850621
PRIORITY APPLN. INFO.:			DE 1984-3422962	A 19840622
			DE 1984-3443468	A 19841129

IT 60940-34-3 81743-90-0 81743-91-1  
81743-98-8 81743-99-9 81744-04-9  
81744-10-7 101563-17-1 101563-18-2  
101563-19-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(condensation of, with glutathione)


RN 60940-34-3 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (CA INDEX NAME)




RN 81743-90-0 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 81743-91-1 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 81743-98-8 CAPLUS


CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/515,678




RN 81743-99-9 CAPLUS

CN Benzonitrile, 4-(3-oxo-1,2-benzisoselenazol-2(3H)-yl)- (9CI) (CA INDEX NAME)




RN 81744-04-9 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 6-fluoro-2-phenyl- (9CI) (CA INDEX NAME)



RN 81744-10-7 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 7-methoxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 101563-17-1 CAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

10/515,678


NAME)



RN 101563-18-2 CAPLUS


CN 1,2-Benziselenazol-3(2H)-one, 2-(4-chloro-3-methoxyphenyl)- (9CI)  
(CA

INDEX NAME)





RN 101563-19-3 CAPLUS

CN 1,2-Benziselenazol-3(2H)-one, 2-(3-fluorophenyl)- (9CI) (CA INDEX  
NAME)



GI

10/515,678



AB The title compds. I [R1-R4 = H, halo, alkyl, alkoxy, CF3, NO2, cyano, OH],

useful in medicine for inhibition of liver damage, heart infarction, inflammation, and radiation damage, etc. (no data), were prepared by condensation of benziselenazolinone II with glutathione.

Thus,

II (R1-R4 = H) in DMF was added to glutathione in H2O. The resulting mixture became a clear solution and after a few min I (R1-R4 = H) precipitated in 92.8% yield. I can be administered in the form of suppositories, parenteral injections etc.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
442.53	802.50

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-63.96	-63.96

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:20:14 ON 02 MAY 2007